Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press194210.17650/1726-9776-2025-21-1-126-129RESOLUTIONРЕЗОЛЮЦИЯApproaches to the treatment of patients with metastatic renal cell carcinoma: resolution following the experts meetingОбсуждение подходов к лечению больных метастатическим почечно-клеточным раком: резолюция по итогам совещания экспертов090520252111261290905202509052025https://oncourology.abvpress.ru/oncur/article/view/1942

.

27 июня 2024 г. в ГАУЗ НО «НИИ клинической онкологии «Нижегородский областной клинический онкологический диспансер» состоялось совещание экспертов «Изменение парадигмы лечения пациентов с метастатическим почечно-клеточным раком» в целях обсуждения существующих подходов к терапии распространенного почечно-клеточного рака в Нижнем Новгороде и Нижегородской области, нерешенных задач по оказанию помощи больным на разных этапах, накопленного опыта применения комбинированной иммунотаргетной терапии, критериев выбора 1-й линии терапии при светлоклеточном и несветлоклеточном почечно-клеточном раке, изменения подхода к выбору 1-й линии терапии с 2024 г. в связи с обновлением Клинических рекомендаций Минздрава Российской Федерации по лечению рака почки от 06.12.2023.

Renal parenchyma cancer. Clinical guidelines of the Ministry of Health of Russia. 2023. Available at: https://cr.minzdrav.gov.ru/ schema/10_4 (date of access: 01.02.2024). (In Russ.).Рак паренхимы почки. Клинические рекомендации Минздрава России. 2023. Доступно по: https://cr.minzdrav.gov.ru/schema/10_4 (дата обращения: 01.02.2024).Motzer R.J., Porta C., Eto M. et al. Phase 3 trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) monotherapy as a first-line treatment for patients (pts) with advanced renal cell carcinoma (RCC) (CLEAR study). J Clin Oncol 2021;39(suppl 6):269. DOI: 10.1200/JCO.2021.39.6_suppl.269Nocera L., Karakiewicz P.I., Wenzel M. et al. Clinical outcomes and adverse events after first-line treatment in metastatic renal cell carcinoma: a systematic review and network meta-analysis. J Urol 2022;207(1):16–24. DOI: 10.1097/JU.0000000000002252Volkova M.I., Alekseev B.Ya., Gladkov O.A. et al. Practical recommendations for drug treatment of renal cell carcinoma. Zlokachestvennye opukholi: prakticheskie rekomendatsii = Malignant Tumors: Practical Recommendations RUSSCO 2022;3s2(12):579–88. (In Russ.).Волкова М.И., Алексеев Б.Я., Гладков О.А. и др. Практические рекомендации по лекарственному лечению почечноклеточного рака. Злокачественные опухоли: практические рекомендации RUSSCO 2022;3s2(12):579–88.Motzer R., Porta C., Eto M. et al. Final prespecified overall survival (OS) analysis of CLEAR: 4-year follow-up of lenvatinib plus pembrolizumab (L+P) vs sunitinib (S) in patients (pts) with advanced renal cell carcinoma (aRCC). J Clin Oncol 2023;41.16_ suppl:4502–4502. DOI: 10.1200/JCO.2023.41.16_suppl.4502Grunwald V. Poster presented at the ASCO Annual Meeting. 04–08 June, 2021. Virtual Format; abstract # 4560.Zang P.D., Angeles A., Dorff T.B. et al. Immuno-oncology advances in genitourinary cancers. Am Soc Clin Oncol Educ Book 2024;44(2):e430428. DOI: 10.1200/EDBK_43042Grunwald V., Powles T., Eto M. et al. Phase 3 CLEAR study in patients with advanced renal cell carcinoma: outcomes in subgroups for the lenvatinib-plus-pembrolizumab and sunitinib arms. Front Oncol 2023;13:1223282. DOI: 10.3389/fonc.2023.1223282Sawaya G.B.N., Dragomir A., Wood L.A. et al. Real-world assessment of clinical outcomes in patients with metastatic renal cell carcinoma with or without sarcomatoid features treated with firstline systemic therapies. Eur Urol Oncol 2024;7(3):570–80. DOI: 10.1016/j.euo.2023.11.016Barata P., Tangen C., Plets M. et al. Final overall survival analysis of S1500: a randomized, phase II study comparing sunitinib with cabozantinib, crizotinib, and savolitinib in advanced papillary renal cell carcinoma. J Clin Oncol 2024;42(33):3911–6. DOI: 10.1200/JCO.24.00767Clinical Practice Guidelines in Oncology. Kidney cancer, version 2.2024. NCCN. Available at: https://www.nccn.org/professionals/ physician_gls/pdf/kidney.pdf (date of access: 03.02.2024).Clinical Practice Guidelines in Oncology. Kidney cancer, version 2.2024. NCCN. Available at: https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf (date of access: 03.02.2024).Choueiri T.K., Eto M., Motzer R. et al. Lenvatinib plus pembrolizumab versus sunitinib as first-line treatment of patients with advanced renal cell carcinoma (CLEAR): extended follow-up from the phase 3, randomised, open-label study. Lancet Oncol 2023;24(3):228–38. DOI: 10.1016/S1470-2045(23)00049-9Motzer R., Porta C., Alekseev B. et al. Health-related quality-of-life outcomes in patients with advanced renal cell carcinoma treated with lenvatinib plus pembrolizumab or everolimus versus sunitinib (CLEAR): a randomised, phase 3 study [published online ahead of print, 2022 Apr 27]. Lancet Oncol 2022;(6):768–80. DOI: 10.1016/S1470-2045(22)00212-1Albiges L., Tannir N.M., Burotto M. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 4-year follow-up of the phase III CheckMate 214 trial. ESMO Open 2020;5(6):e001079. DOI: 10.1136/esmoopen-2020-001079Powles T., Plimack E.R., Soulieres D. et al. Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial [published correction appears in Lancet Oncol 2020;21(12):e553]. Lancet Oncol 2020;21(12):1563–73. DOI: 10.1016/S1470-2045(20)30436-8Choueiri T.K., Powles T., Burotto M. et al. Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma. N Engl J Med 2021;384(9):829–41. DOI: 10.1056/NEJMoa2026982Motzer R.J., Penkov K., Haanen J. et al. Avelumab plus axitinib versus sunitinib for advanced renalcell carcinoma. N Engl J Med 2019;380(12):1103–15. DOI: 10.1056/NEJMoa1816047Suarez C., Larkin J.M.G., Patel P. et al. Phase II study investigating the safety and efficacy of savolitinib and durvalumab in metastatic papillary renal cancer (CALYPSO) [published correction appears in J Clin Oncol 2023;41(23):3961]. J Clin Oncol 2023;41(14): 2493–502. DOI: 10.1200/JCO.22.01414Bergmann L., Albiges L., Ahrens M. et al. Interdisciplinary Renal Cell Carcinoma Working Group of the DKG (IAGN). Prospective randomised phase-II trial of ipilimumab/nivolumab versus standard of care in non-clear cell renal cell cancer – results of the SUNNIFORECAST trial. Ann Oncol 2025:S0923-7534(25)00124-3. DOI: 10.1016/j.annonc.2025.03.016Tannir N.M., Albigès L., McDermott D.F. et al. Nivolumab plus ipilimumab versus sunitinib for first-line treatment of advanced renal cell carcinoma: extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial. Ann Oncol 2024;35(11):1026–38. DOI: 10.1016/j.annonc.2024.07.727